In3Bio Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Bioven 3 Limited (to 2019)
0
Ending by 2030
Nov 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,902,760 | Recombinant Proteins and Their Therapeutic Uses In force · High confidence | In force | High confidence | |
| US 11,198,716 | Recombinant Proteins and Their Therapeutic Uses In force · High confidence | In force | High confidence | |
| US 12,030,920 | Recombinant Proteins and Their Therapeutic Uses In force · High confidence | In force | High confidence | |
| US 12,570,708 | Recombinant Proteins and Their Therapeutic Uses In force · Medium confidence | In force | Medium confidence | |
| US 11,419,923 | Self-Assembling Synthetic Proteins In force · High confidence | In force | High confidence | |
| US 12,433,939 | Self-Assembling Synthetic Proteins Comprising Cholera Toxin Beta Subunit In force · Medium confidence | In force | Medium confidence | |
| US 10,736,948 | Epidermal Growth Factor Fusion Proteins with Mutant Cholera Toxin B Subunits In force · High confidence | In force | High confidence | |
| US 12,595,297 | Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Tyrosine Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 12,258,389 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,257,245 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned